Literature DB >> 17577036

Identifying stage III colorectal cancer patients: the influence of the patient, surgeon, and pathologist.

Eva Judith Ann Morris1, Nicola Joanne Maughan, David Forman, Philip Quirke.   

Abstract

PURPOSE: Nodal yields from resected colorectal cancers vary greatly. This study sought to determine what patient, tumor, and management factors influence the number of nodes retrieved and to determine if the extent of lymphadenectomy affects stage allocation and influences survival. PATIENTS AND METHODS: Retrospective study of the nodal yields of 7,062 surgically resected colorectal cancer patients for whom colorectal pathology minimum data sets had been collected. The percentage of patients diagnosed as stage III was compared across nodal yield categories. A threshold for an adequate lymphadenectomy was defined as retrieval of 12 nodes. Binary logistic regression was used to determine factors associated with obtaining an adequate lymphadenectomy.
RESULTS: Median nodal yields increased over the study period from 7 (interquartile range [IQR], 4 to 11) in 1995 to 13 (IQR 8 to 19) in 2003. There was no difference in yield by cancer site or sex, but yields were lower in older patients. Yields increased with increasing local invasion and stage of tumor. The percentage of patients diagnosed as stage III increased as yields increased. Five-year survival was lower in those patients who did not have an adequate lymphadenectomy. Adequate lymphadenectomy was significantly more likely in patients with advanced tumors and when the surgery and pathology was undertaken by a specialist. Older patients were significantly less likely to receive an adequate lymphadenectomy.
CONCLUSION: Variations in nodal yield are due to idiosyncratic patient and tumor characteristics and differences in the quality of surgery and pathology undertaken. Adequate lymphadenectomy is essential to ensure correct stage allocation and optimal survival.

Entities:  

Mesh:

Year:  2007        PMID: 17577036     DOI: 10.1200/JCO.2007.11.0445

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  33 in total

1.  Number of lymph nodes after neoadjuvant therapy for rectal cancer: How many are needed?

Authors:  Stefano Scabini; Valter Ferrando
Journal:  World J Gastrointest Surg       Date:  2012-02-27

2.  More is not always better.

Authors:  Luis A Carriquiry
Journal:  World J Surg       Date:  2011-12       Impact factor: 3.352

3.  Effects of neoadjuvant chemotherapy plus chemoradiotherapy on lymph nodes in rectal adenocarcinoma.

Authors:  Guillaume Chotard; Maylis Capdepont; Quentin Denost; Denis Smith; Véronique Vendrely; Eric Rullier; Anne Rullier
Journal:  Virchows Arch       Date:  2021-05-13       Impact factor: 4.064

Review 4.  EURECCA consensus conference highlights about colorectal cancer clinical management: the pathologists expert review.

Authors:  P Quirke; N P West; I D Nagtegaal
Journal:  Virchows Arch       Date:  2014-01-24       Impact factor: 4.064

5.  Complete mesocolic excision with D3 lymph node dissection in laparoscopic colectomy for stages II and III colon cancer: long-term oncologic outcomes in 168 patients.

Authors:  J W Shin; A H Y Amar; S H Kim; J M Kwak; S J Baek; J S Cho; J Kim
Journal:  Tech Coloproctol       Date:  2014-03-15       Impact factor: 3.781

6.  Adjuvant therapy decisions based on magnetic resonance imaging of extramural venous invasion and other prognostic factors in colorectal cancer.

Authors:  M Chand; R I Swift; I Chau; R J Heald; P P Tekkis; G Brown
Journal:  Ann R Coll Surg Engl       Date:  2014-10       Impact factor: 1.891

7.  Lymph Node Harvest After Neoadjuvant Treatment for Rectal Cancer and Its Impact on Oncological Outcomes.

Authors:  Rajkumar Billakanti; Ramakrishnan Ayloor Seshadri; Srikanth Soma; Hemanth Makineni; Shirley Sundersingh
Journal:  Indian J Surg Oncol       Date:  2020-07-24

8.  Stage II/III rectal cancer with intermediate response to preoperative radiochemotherapy: do we have indications for individual risk stratification?

Authors:  Thilo Sprenger; Hilka Rothe; Klaus Jung; Hans Christiansen; Lena C Conradi; B Michael Ghadimi; Heinz Becker; Torsten Liersch
Journal:  World J Surg Oncol       Date:  2010-04-13       Impact factor: 2.754

9.  Impact of HLA-E gene polymorphism on HLA-E expression in tumor cells and prognosis in patients with stage III colorectal cancer.

Authors:  Zi-Jun Zhen; Jia-Yu Ling; Yue Cai; Wen-Biao Luo; You-Jian He
Journal:  Med Oncol       Date:  2013-02-03       Impact factor: 3.064

10.  Preoperative chemoradiotherapy does not necessarily reduce lymph node retrieval in rectal cancer specimens--results from a prospective evaluation with extensive pathological work-up.

Authors:  Thilo Sprenger; Hilka Rothe; Kia Homayounfar; Tim Beissbarth; B Michael Ghadimi; Heinz Becker; Torsten Liersch
Journal:  J Gastrointest Surg       Date:  2009-10-15       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.